The Use of Reimbursement Data for Timely Monitoring of Vaccination Coverage: The Example of Human Papillomavirus Vaccine Following Public Concerns About Vaccine Safety

Background

Since 2011 public concerns about Human Papillomavirus (HPV) vaccination safety and efficacy arose in France. We explored the relevance of using vaccines reimbursement data to assess the impact of those public concerns on vaccination coverage.

Methods

We used the Permanent Sample of Beneficiaries which was, at the time of the study, a representative sample of 1/97 ^th health insurance beneficiaries of the main Social Security scheme, the General Health Insurance Scheme, covering approximately 77 % of the French resident population. We estimated HPV vaccination coverage among girls born between 1995 and 1999 at their 15 ^th , 16 ^th and 17 ^th birthday.

Results

The coverage for complete vaccination among 16 years old girls decreased from 26.5 % in the first semester of 2011 to 18.6 % in the first semester of 2014.

Conclusions

HPV vaccination coverage was already low in 2011 and continued to decrease thereafter. Vaccines reimbursement data allowed us to reactively monitor the impact of the controversy on vaccination coverage and design counteracting measures.

Below:  Vaccination coverage with one dose of HPV vaccine at 15 th birthday and three doses at 16 th birthday, by quarter periods, January 2010–June 2014

Below:  Cumulative vaccination coverage for 3 doses of HPV vaccine according to age and half year of birth. France

Full article at:   http://goo.gl/pTup37

By:   Laure Fonteneau¹², Marine Ragot¹, Isabelle Parent du Châtelet¹, Jean-Paul Guthmann¹and Daniel Lévy-Bruhl^1*

¹Institut de Veille Sanitaire (InVS), Saint-Maurice, France

²European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, (ECDC), Stockholm, Sweden

 

More at:  https://twitter.com/hiv_insight

And: http://twitter.com/Prison_Health